Additionally, implementation of iNKT cells as a strategy for cell-based immunotherapy offers several other advantages, such as eliminating the risk of graft versus host disease (GvHD) from lack of MHC engagement as well as ancillary remediation of the TME through cytotoxic killing of CD1d-expressing TAMs and MDSCs (29, 41–43). The gene discussed is HLA-C; the disease is graft versus host disease.